Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Nanoparticle-mediated ocular delivery of novel NAD-boosting small molecules for ophthalmic disease.

Objectif

Metabolic decline may be a critical, and treatable, pathogenic component of glaucoma. Glaucoma is one of the most prevalent neurodegenerations worldwide, affecting 80 million patients worldwide. There are no neuroprotective therapies.
We have discovered metabolic and mitochondrial dysfunction in the retina and optic nerve which occur prior to neurodegeneration in glaucoma. One of these early changes is a decline in the important metabolite nicotinamide adenine dinucleotide (NAD), which critically regulates neuronal survival in glaucoma. Preventing NAD decline pharmacologically or through targeted gene therapies robustly prevents neurodegeneration. We are now actively generating novel NAD-generating compounds based on our initial studies. Neuronal NAD production is an ideal target for neuroprotective drug discovery for neuroprotection in glaucoma and other axon degenerations.
The goal of this research project is to develop clinically translatable nano-enabled neuroprotective strategies for glaucoma. I will focus on these novel strategies involving compounds that increase NAD metabolism developed by the Williams lab and formulated in nanocarriers by the Sotiriou lab. These will be translated into practical, effective agents that provide long-term effects in the retina. The current challenges we face are: (1) ocular delivery without toxicity, (2) high pay-load delivery, (3) delivery with sustained release. To overcome these, the Williams and Sotiriou labs will collaborate, where I will: (1) rationally design biocompatible nanocarriers by flame spray pyrolysis, (2) load these nanocarriers with novel NAD-generating drugs, (3) evaluate their NAD-generating capacity in vivo and the resulting neuroprotective effects. With this project, I will combine the expertise from the two laboratories to facilitate the integration of visual neuroscience, pharmacology, and nanoscale drug delivery systems to develop clinically translatable therapies for ophthalmic disease.

Champ scientifique (EuroSciVoc)

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-MSCA-2024-PF-01

Voir tous les projets financés au titre de cet appel

Coordinateur

KAROLINSKA INSTITUTET
Contribution nette de l'UE
€ 252 180,00
Adresse
NOBELS VAG 5
171 77 STOCKHOLM
Suède
Région
Östra Sverige Stockholm Stockholms län
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
Aucune donnée